Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd

JurisdictionAustralia Federal only
CourtHigh Court
JudgeFrench CJ.,Hayne J,Crennan,Kiefel JJ.,Gageler J.
Judgment Date04 December 2013
Neutral Citation2013-1204 HCA A,[2013] HCA 50
Docket NumberS219/2012 & S1/2013
Date04 December 2013
    • This document is available in original version only for vLex customers

      View this document and try vLex for 7 days
    • TRY VLEX
6 cases
  • Alphapharm Pty Ltd v H Lundbeck A/S
    • Australia
    • High Court
    • 5 November 2014
    ...Act. See, generally, Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (2013) 88 ALJR 261 at 302–303 [186]–[193]; 304 ALR 1 at 51–53; [2013] HCA 50. 79 IPAC Report at 5 80 ‘Government Response to the Report of the Industrial Property Advisory Committee, “Patents, Innovation and Competition ......
  • Australian Financial Services and Leasing Pty Ltd v Hills Industries Ltd
    • Australia
    • High Court
    • 7 May 2014
    ...Australian law: Competition and Consumer Act 2010 (Cth), Sched 2 — Australian Consumer Law, ss 18, 20, 21, 22.See also Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (2013) 88 ALJR 261 at 270 [17]–[18] per French CJ, 283–284 [71]–[72] per Hayne J; 304 ALR 1 at 9–10, 27; [2013] HCA 50 i......
  • D'Arcy v Myriad Genetics Inc.
    • Australia
    • High Court
    • 7 October 2015
    ...attempt to place upon the idea the fetters of an exact verbal formula could never have been sound.’ Hayne J made it in Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd47: ‘Nothing said in the Court's reasons for decision in that case can be taken as an exact verbal formula which alone capt......
  • InterPharma Pty Ltd v Hospira, Inc (No 5)
    • Australia
    • Federal Court
    • 20 June 2019
    ...X in the manufacture of a medicament for a specified (and new) therapeutic use”: see Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd [2013] HCA 50; 253 CLR 284 (Apotex v Sanofi-Aventis HCA) at [248]. 32 In Otsuka Pharmaceutical Co Ltd v Generic Health Pty Ltd (No 4) [2015] FCA 634; 113 IP......
  • Request a trial to view additional results
13 firm's commentaries
  • News from Abroad -- Swiss-type Patent Claims in Australia
    • Australia
    • JD Supra Australia
    • 1 August 2019
    ...Lambert Company LLC v Generics (UK) Ltd t/a Mylan and another [2018] UKSC 56. [5] Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd [2013] HCA 50. As are claims to therapeutics in ‘when used’ format, which have essentially the same scope as method claims, see Wellcome Foundation Ltd v Commi......
  • News from Abroad: High Court of Australia Hears Myriad Appeal
    • Australia
    • JD Supra Australia
    • 17 June 2015
    ...Development Corporation v Commissioner of Patents (1959) 102 CLR 252; endorsed by the High Court in Apotex Pty Ltd v Sanofi Aventis [2013] HCA 50. 4 IPTA Submissions at [34]. 5 Attorney-General's Submissions at [6]. 6 Ibid at [10]. 7 Association for Molecular Pathology v Myriad Genetics 569......
  • Methods of medical treatment patentable in Australia; infringement by cross-label use is fact-dependent
    • Australia
    • Mondaq Australia
    • 13 December 2013
    ...demonstrate that indirect infringement will depend on the facts in each case (Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd [2013] HCA 50). Sanofi's psoriasis compound and Apotex's Sanofi-Aventis Deutschland GmbH was the registered owner of a patent which claimed a method of preventing ......
  • The High Court gives generics the rubber-stamp for 'skinny labelling' (but no surprises on method of treatment patents)
    • Australia
    • Mondaq Australia
    • 9 February 2014
    ...Apotex v Sanofi-Aventis [2013] HCA 50 the High Court finally confirmed (what was fairly well understood all along) that methods of medical treatment are patentable subject matter in Australia. However, it remains uncertain whether medical/surgical procedures are patentable. The High Court's......
  • Request a trial to view additional results

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT